Skip to main content

Table 9 Impact of differences in EQ-5D index scores using UK, US, and Japan preference weights on ICUR for 7 hypothetical decision trees

From: A comparison of EQ-5D index scores using the UK, US, and Japan preference weights in a Thai sample with type 2 diabetes

Variables Hypothetical decision tree
  1 2 3 4 5 6 7
EQ-5D index scores when the drug was effective (success)        
   Drug A 0.900 0.951 0.916 0.967 0.935 0.928 0.981
   Drug B 0.800 0.851 0.816 0.867 0.835 0.828 0.881
EQ-5D index scores when the drug was not effective (failure)        
   Drug A 0.500 0.551 0.516 0.567 0.535 0.528 0.581
   Drug B 0.400 0.451 0.416 0.467 0.435 0.428 0.481
QALY        
   Drug A 6.40 6.81 6.53 6.94 6.68 6.62 7.05
   Drug B 4.00 4.31 4.10 4.40 4.21 4.17 4.49
Incremental cost (Baht) 300,000 300,000 300,000 300,000 300,000 300,000 300,000
Incremental QALY 2.40 2.50 2.43 2.54 2.47 2.45 2.56
ICUR (Baht/QALY) 125,000 119,904 123,457 118,110 121,457 122,150 117,096
% Difference in ICUR from base case (Decision tree 1) - 4.08 1.23 5.51 2.83 2.28 6.32
  1. Decision tree 1 represents the base-case scenario, while decision trees 2–7 mean the scenarios where base-case utility scores overestimated by 0.051 (mean difference between UK versus US weights), 0.016 (mean difference between UK versus Japan weights), 0.067 (mean difference between US versus Japan weights), 0.035 (median difference between UK versus US weights), 0.028 (median difference between UK versus Japan weights), and 0.081 (median difference between US versus Japan weights).